OVERVIEW
Happy Saturday
Welcome to the Stocks Top 25 Newsletter this week!
The Stocks Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!
Here are the Stocks Top 25 Lists for this week:
S&P 500
Top 25 S&P 500
The S&P 500 Top 25 list -4.45%underperformed the S&P 500 index -1.95%
Newcomers are in blue, and grey names at the bottom were kicked out of last week’s list.
NASDAQ 100
The Large-Cap Nasdaq 100
The Nasdaq 100 Top 25 list -3.51%underperformed the Nasdaq 100 index -3.07%
Newcomers are in blue, and grey names at the bottom were kicked out of last weeks list.
RUSSELL 2000
The Growth-Centric Russell 2000
The Russell 2000 Top 25 list -2.99%underperformed the Russell 2000 index -0.78%
Newcomers are in blue, and grey names at the bottom were kicked out of last weeks list.
Top Dawg Of The Week
The Top 25 list's Top Dawg was $OLMA ( ▲ 5.27% ) Flying 175.83%!!
Olema Pharmaceuticals surges on Roche validation::
Olema Pharmaceuticals’ shares jumped after $RHHBY ( ▲ 2.28% ) announced positive Phase 3 results for its oral SERD, giredestrant. The trial showed a statistically significant improvement in invasive disease‑free survival versus standard endocrine therapy in ER‑positive, HER2‑negative, early‑stage breast cancer. This marks the first oral SERD to demonstrate benefit in the adjuvant setting, a multi‑billion‑dollar market.
Investor impact: Roche’s success is seen as external validation for the SERD drug class. Olema’s lead candidate, palazestrant (OP‑1250), is both a complete estrogen receptor antagonist (CERAN) and SERD. Because it works via the same mechanism, investors view Roche’s data as reducing scientific risk for Olema’s program.
Big picture: Palazestrant is in pivotal Phase 3 trials for metastatic breast cancer. Roche’s breakthrough strengthens confidence in Olema’s pipeline and positions the company as a potential next mover in a validated, high‑value therapeutic space.
Like all biotech companies, Olema spends all of its money on R&D, according to Fiscal.ai